SANTA MONICA, Calif., June 11 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , one of the largest umbilical cord blood stem cell preservation companies (http://www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today it has begun due diligence for sales operation expansion into the European Union, specifically Belgium and Italy.
Cord Blood America's international partner, a.bourkas Co., United, has had operations in Greece since 2006 and has established a sales operation in Germany.
"This is potentially a very profitable new frontier in the stem cell industry and we are pleased to be one of the leaders in this expansion and growth," said founder and CEO Matthew Schissler. "We started small in Europe, and believe now, for a number of fiscal reasons, would be a good time to look at expansion. The value of storing umbilical cord blood stem cells at birth is becoming well known worldwide."
About Cord Blood America
Cord Blood America (BULLETIN BOARD: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com
Cord Blood America, Inc.
CONTACT: Paul Knopick of E & E Communications, +1-949-707-5365,
pknopick@eandecommunications.com
Web Site: http://www.cordblood-america.com/
http://www.corcell.com/
